BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35135099)

  • 1. Retrospective Survival Analysis of Patients With Advanced Pancreatic Ductal Adenocarcinoma and Germline
    Reiss KA; Yu S; Judy R; Symecko H; Nathanson KL; Domchek SM
    JCO Precis Oncol; 2018 Nov; 2():1-9. PubMed ID: 35135099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective Survival Analysis of Patients With Resected Pancreatic Ductal Adenocarcinoma and a Germline
    Yu S; Agarwal P; Mamtani R; Symecko H; Spielman K; O'Hara M; O'Dwyer PJ; Schneider C; Teitelbaum U; Nathanson KL; Domchek SM; Reiss KA
    JCO Precis Oncol; 2019 Dec; 3():1-11. PubMed ID: 35100679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in Taiwan.
    Cheng SM; Su YY; Chiang NJ; Wang CJ; Chao YJ; Huang CJ; Tsai HJ; Chen SH; Chang CY; Tsai CR; Li YJ; Yen CJ; Chuang SC; Chang JS; Shan YS; Hwang DY; Chen LT
    J Biomed Sci; 2024 Feb; 31(1):21. PubMed ID: 38350919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma.
    Blair AB; Groot VP; Gemenetzis G; Wei J; Cameron JL; Weiss MJ; Goggins M; Wolfgang CL; Yu J; He J
    J Am Coll Surg; 2018 Apr; 226(4):630-637.e1. PubMed ID: 29309945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platinum-based chemotherapy for pancreatic cancer: impact of mutations in the homologous recombination repair and Fanconi anemia genes.
    Emelyanova M; Pudova E; Khomich D; Krasnov G; Popova A; Abramov I; Mikhailovich V; Filipenko M; Menshikova S; Tjulandin S; Pokataev I
    Ther Adv Med Oncol; 2022; 14():17588359221083050. PubMed ID: 35309086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Germline Mutations in Homologous Recombination Repair Genes on Overall Survival of Patients with Pancreatic Adenocarcinoma.
    Yadav S; Kasi PM; Bamlet WR; Ho TP; Polley EC; Hu C; Hart SN; Rabe KG; Boddicker NJ; Gnanaolivu RD; Lee KY; Lindstrom TH; Petersen GM; Couch FJ; McWilliams RR
    Clin Cancer Res; 2020 Dec; 26(24):6505-6512. PubMed ID: 33028596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis.
    Rebelatto TF; Falavigna M; Pozzari M; Spada F; Cella CA; Laffi A; Pellicori S; Fazio N
    Cancer Treat Rev; 2019 Nov; 80():101895. PubMed ID: 31542591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection.
    Park W; Chen J; Chou JF; Varghese AM; Yu KH; Wong W; Capanu M; Balachandran V; McIntyre CA; El Dika I; Khalil DN; Harding JJ; Ghalehsari N; McKinnell Z; Chalasani SB; Makarov V; Selenica P; Pei X; Lecomte N; Kelsen DP; Abou-Alfa GK; Robson ME; Zhang L; Berger MF; Schultz N; Chan TA; Powell SN; Reis-Filho JS; Iacobuzio-Donahue CA; Riaz N; O'Reilly EM
    Clin Cancer Res; 2020 Jul; 26(13):3239-3247. PubMed ID: 32444418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer.
    Golan T; Sella T; O'Reilly EM; Katz MH; Epelbaum R; Kelsen DP; Borgida A; Maynard H; Kindler H; Friedmen E; Javle M; Gallinger S
    Br J Cancer; 2017 Mar; 116(6):697-702. PubMed ID: 28183138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.
    Golan T; Kanji ZS; Epelbaum R; Devaud N; Dagan E; Holter S; Aderka D; Paluch-Shimon S; Kaufman B; Gershoni-Baruch R; Hedley D; Moore MJ; Friedman E; Gallinger S
    Br J Cancer; 2014 Sep; 111(6):1132-8. PubMed ID: 25072261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma.
    Takeuchi S; Doi M; Ikari N; Yamamoto M; Furukawa T
    Sci Rep; 2018 May; 8(1):8105. PubMed ID: 29802286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization.
    Kadouri L; Rottenberg Y; Zick A; Hamburger T; Lipson D; Peretz T; Nechushtan H
    Lung Cancer; 2019 Nov; 137():48-51. PubMed ID: 31542568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in
    Reiss KA; Mick R; O'Hara MH; Teitelbaum U; Karasic TB; Schneider C; Cowden S; Southwell T; Romeo J; Izgur N; Hannan ZM; Tondon R; Nathanson K; Vonderheide RH; Wattenberg MM; Beatty G; Domchek SM
    J Clin Oncol; 2021 Aug; 39(22):2497-2505. PubMed ID: 33970687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX.
    Sehdev A; Gbolahan O; Hancock BA; Stanley M; Shahda S; Wan J; Wu HH; Radovich M; O'Neil BH
    Clin Cancer Res; 2018 Dec; 24(24):6204-6211. PubMed ID: 30131383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced-stage Müllerian cancer.
    Mahdi H; Gockley A; Esselen K; Marquard J; Nutter B; Yang B; Hinchcliff E; Horowitz N; Rose PG
    Gynecol Oncol; 2015 Dec; 139(3):407-12. PubMed ID: 26210778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.
    Lowery MA; Kelsen DP; Capanu M; Smith SC; Lee JW; Stadler ZK; Moore MJ; Kindler HL; Golan T; Segal A; Maynard H; Hollywood E; Moynahan M; Salo-Mullen EE; Do RKG; Chen AP; Yu KH; Tang LH; O'Reilly EM
    Eur J Cancer; 2018 Jan; 89():19-26. PubMed ID: 29223478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer - an observational cohort study.
    Unni SK; Schauerhamer MB; Deka R; Tyczynski JE; Fernandes AW; Stevens V; Brixner DI; Stenehjem DD
    J Ovarian Res; 2016 Mar; 9():18. PubMed ID: 27004793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program.
    Pishvaian MJ; Blais EM; Brody JR; Rahib L; Lyons E; De Arbeloa P; Hendifar A; Mikhail S; Chung V; Sohal DPS; Leslie S; Mason K; Tibbets L; Madhavan S; Matrisian LM; Petricoin E
    JCO Precis Oncol; 2019 Dec; 3():1-10. PubMed ID: 35100730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.
    Moffat GT; O'Reilly EM
    Clin Adv Hematol Oncol; 2020 Mar; 18(3):168-179. PubMed ID: 32609666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.
    Yang D; Khan S; Sun Y; Hess K; Shmulevich I; Sood AK; Zhang W
    JAMA; 2011 Oct; 306(14):1557-65. PubMed ID: 21990299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.